Search results
Results from the WOW.Com Content Network
Several germline KRAS mutations have been found to be associated with Noonan syndrome [13] and cardio-facio-cutaneous syndrome. [14] Somatic KRAS mutations are found at high rates in leukemias, colorectal cancer, [15] pancreatic cancer [16] and lung cancer. [17]
Selumetinib, had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, [5] and is now in phase III development in KRAS mutation positive NSCLC (SELECT-1, NCT01933932). Other ph 3 clinical trials underway include uveal melanoma (failed), and differentiated thyroid carcinoma.
mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna. [1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene. [ 2 ] It is currently being evaluated for the treatment of either non-small cell lung cancer , colorectal cancers with microsatellite instability , or ...
HCT116 cells have a mutation in codon 13 of the KRAS proto-oncogene, and are suitable transfection targets for gene therapy research. [2] The cells have an epithelial morphology and can metastasize in xenograft models. [1] When transducted with viral vectors carrying the p53 gene, HCT116 cells remain arrested in the G1 phase. [3]
Notable examples of potentially predictive cancer biomarkers include mutations on genes KRAS, p53, EGFR, erbB2 for colorectal, esophageal, liver, and pancreatic cancer; mutations of genes BRCA1 and BRCA2 for breast and ovarian cancer; abnormal methylation of tumor suppressor genes p16, CDKN2B, and p14ARF for brain cancer; hypermethylation of ...
Mutation of deoxycytidine kinase or loss of expression results in resistance to arabinoside. [2] Growth factor expression levels can also promote resistance to antineoplastic therapies. [2] In breast cancer, drug resistant cells were found to express high levels of IL-6, while sensitive cells did not express significant levels of the growth factor.
The signs and symptoms of colorectal cancer depend on the location of the tumor in the bowel, and whether it has spread elsewhere in the body ().The classic warning signs include: worsening constipation, blood in the stool, decrease in stool caliber (thickness), loss of appetite, loss of weight, and nausea or vomiting in someone over 50 years old. [15]
The most common cancer among women in the United States is breast cancer (123.7 per 100,000), followed by lung cancer (51.5 per 100,000) and colorectal cancer (33.6 per 100,000), but lung cancer surpasses breast cancer as the leading cause of cancer death among women. [13]